Lewin Andrew C, Hu Jennifer, Liu Chin-Chi, Camacho Pilar, Carter Renee T
Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
Vet Ophthalmol. 2025 Mar;28(2):150-157. doi: 10.1111/vop.13109. Epub 2023 May 13.
To evaluate the efficacy of 2% dorzolamide ophthalmic solution for reduction of postoperative ocular hypertension (POH) following routine phacoemulsification surgery in dogs.
Thirty one dogs (53 eyes) with naturally occurring cataracts undergoing routine phacoemulsification surgery.
PROCEDURE(S): A prospective, double-masked, randomized, placebo-controlled study design was utilized. Dogs received 2% dorzolamide ophthalmic solution or saline 1 h prior to surgery then three times daily for 21 days postoperatively in the operated eye(s). Intraocular pressure (IOP) was recorded 1 h prior to surgery and 3 h, 7 h, 22 h, 1 week and 3 weeks postoperatively. Statistical analyses were performed using chi-squared and Mann-Whitney U test with a significance level of p < .05.
Postoperative ocular hypertension (IOP ≥25 mmHg, <24 h after surgery) occurred in 28/53 (52.8%) eyes. There was significant reduction in the incidence of POH for eyes receiving dorzolamide (10/26 (38.4%) eyes) versus eyes receiving placebo (18/27 (66.7%) eyes) (p = .0384). Animals were followed for a median of 163 days after surgery. Thirty-seven (37/53 (69.8%)) eyes were visual at final examination and 3/53 (5.7%) globes were enucleated postoperatively. At last follow-up, there was no difference in visual status (p = .9280), need for topical IOP lowering medication (p = .8319) or incidence of glaucoma (p = .5880) based on treatment group.
Perioperative administration of topical 2% dorzolamide reduced the incidence of POH after phacoemulsification in the dogs studied. However, this was not associated with differences in visual outcome, incidence of glaucoma or need for IOP-lowering medications.
评估2%多佐胺滴眼液在降低犬常规超声乳化白内障吸除术后高眼压（POH）中的疗效。
31只患有自然性白内障的犬（53只眼）接受常规超声乳化白内障吸除术。
采用前瞻性、双盲、随机、安慰剂对照研究设计。犬在手术前1小时接受2%多佐胺滴眼液或生理盐水，然后在术后患眼每天滴眼3次，持续21天。分别在手术前1小时、术后3小时、7小时、22小时、1周和3周记录眼压（IOP）。采用卡方检验和Mann-Whitney U检验进行统计学分析，显著性水平为p < 0.05。
术后高眼压（眼压≥25 mmHg，术后<24小时）发生在28/53（52.8%）只眼中。接受多佐胺治疗的眼（10/26（38.4%）只眼）术后高眼压的发生率显著低于接受安慰剂治疗的眼（18/27（66.7%）只眼）（p = 0.0384）。术后对动物进行了中位时间为163天的随访。在最后一次检查时，37/53（69.8%）只眼视力正常，3/53（5.7%）只眼球在术后被摘除。在最后一次随访时，基于治疗组，视力状态（p = 0.9280）、局部降眼压药物的使用需求（p = 0.8319）或青光眼的发生率（p = 0.5880）均无差异。
在本研究的犬中，围手术期局部应用2%多佐胺可降低超声乳化白内障吸除术后高眼压的发生率。然而，这与视力预后、青光眼发生率或降眼压药物使用需求的差异无关。
